Literature DB >> 8986129

Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta.

K L Marsh1, E Willmore, S Tinelli, M Cornarotti, E L Meczes, G Capranico, L M Fisher, C A Austin.   

Abstract

Site-specific DNA cleavage by topoisomerase II (EC 5.99.1.3) is induced by many antitumour drugs. Although human cells express two genetically distinct topoisomerase II isoforms, thus far the role and determinants of drug-induced DNA cleavage have been examined only for alpha. Here we report the first high-resolution study of amsacrine (mAMSA) induced DNA breakage by human topoisomerase II beta (overexpressed and purified from yeast) and a direct comparison with the recombinant alpha isoform. DNA cleavage in plasmid pBR322 and SV40 DNA was induced by alpha or beta in the absence or presence of the antitumour agent mAMSA, and sites were mapped using sequencing gel methodology. Low-resolution studies indicated that recombinant human alpha promoted DNA breakage at sites akin to those of beta, although some sites were only cleaved by one enzyme and different intensities were observed at some sites. However, statistical analysis of 70 drug-induced sites for beta and 70 sites for alpha revealed that both isoforms share the same base preferences at 13 positions relative to the enzyme cleavage site, including a very strong preference for A at +1. The result for recombinant alpha isoform is in agreement with previous studies using alpha purified from human cell lines. Thus, alpha and beta proteins apparently form similar ternary complexes with mAMSA and DNA. Previous studies have emphasized the importance of DNA topoisomerase II alpha; the results presented here demonstrate that beta is an in vitro target with similar site determinants, strongly suggesting that beta should also be considered a target of mAMSA in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8986129     DOI: 10.1016/s0006-2952(96)00516-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

2.  Evolutionary History of TOPIIA Topoisomerases in Animals.

Authors:  Filipa Moreira; Miguel Arenas; Arnaldo Videira; Filipe Pereira
Journal:  J Mol Evol       Date:  2022-02-14       Impact factor: 2.395

3.  Thiols oxidation and covalent binding of BSA by cyclolignanic quinones are enhanced by the magnesium cation.

Authors:  Antonio E Alegria; Pedro Sanchez-Cruz; Ajay Kumar; Carmelo Garcia; Fernando A Gonzalez; Aimee Orellano; Beatriz Zayas; Marina Gordaliza
Journal:  Free Radic Res       Date:  2008-01

4.  mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.

Authors:  Kathryn L Gilroy; Chrysoula Leontiou; Kay Padget; Jeremy H Lakey; Caroline A Austin
Journal:  Nucleic Acids Res       Date:  2006-03-20       Impact factor: 16.971

5.  The impact of the human DNA topoisomerase II C-terminal domain on activity.

Authors:  Emma L Meczes; Kathryn L Gilroy; Katherine L West; Caroline A Austin
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

6.  The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery.

Authors:  Kotaro Yamamoto; Taiki Kokubun; Kota Sato; Takahiro Akaishi; Atsushi Shimazaki; Masatsugu Nakamura; Yukihiro Shiga; Satoru Tsuda; Kazuko Omodaka; Hideyuki Saya; Toru Nakazawa
Journal:  Sci Rep       Date:  2019-12-17       Impact factor: 4.379

7.  DNA topoisomerase II selects DNA cleavage sites based on reactivity rather than binding affinity.

Authors:  Felix Mueller-Planitz; Daniel Herschlag
Journal:  Nucleic Acids Res       Date:  2007-05-21       Impact factor: 16.971

8.  C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.

Authors:  René M Linka; Andrew C G Porter; Arsen Volkov; Christian Mielke; Fritz Boege; Morten O Christensen
Journal:  Nucleic Acids Res       Date:  2007-05-25       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.